Company Remodeling and Strategic Partnership Contracts Under Construction

The contract is forming. The contract is the solution to the problem. CytoDyn has garnered sufficient building material, like, cement, mortar, building block and had dug deep enough to reach bedrock, upon which, it foundation may now be built upon. CytoDyn's ongoing remodeling of its ways and means as well as its ongoing discussions together become the Arrangement with which CytoDyn establishes its foot hold into arenas where our roots dig in, shoot forth, spreading and flourishing.

Dr. Cyrus Arman, the new President of CytoDyn had this written about him in a recent Press Release:

"... was responsible for negotiating and implementing transactions, alliances, licensing agreements, and corporate strategy*. Dr. Arman’s prior experience was as the Vice President of Corporate Development and* Strategy at NEUVOGEN, Inc., an early-stage immuno-oncology company, where he was responsible for corporate development, business operations, and corporate strategy functions. Before NEUVOGEN, he was a director in Amgen’s Corporate Strategy group, contributing to rebuilding and running Amgen’s Global Competitive Intelligence and Strategy unit. Dr. Arman began his career as a management consultant, advising clients on complex strategic projects involving multi-billion-dollar business development investments and partnerships in the Biopharma and Diagnostics sectors."

In 4 sentences, the author used the word "Strategy" 6 times. Considering this alone, CytoDyn is at minimum in consideration of a mastermind of multiple "Strategic Partnerships"; at a minimum, a consideration, if not in actuality. The Press Release continuing below, does seem to confirm that a Strategic Partnership is in the making.

“Early in the process, Dr. Arman separated himself from the competition, diving deep into due diligence with a methodical, analytical and inspired approach*. He has the intellectual capacity, experience, and character to* lead CytoDyn into the future*. Leveraging his unique blend of capital markets expertise, corporate governance experience, scientific knowledge and strategic thinking, Dr. Arman has the skills to* competitively position the Company*. The Board expects that CytoDyn will greatly and immediately benefit from Dr. Arman’s strategic ability to analyze and rank the Company’s various opportunities and potential indications,* determine the clinical development path forward*, and* find the right partners to fund and advance the programs*, thereby maximizing shareholder value. We welcome Dr. Arman and could not be more excited about his leadership of our company.”*

Cyrus Arman, Ph.D., stated, “I look forward to uniting our teams and individuals in the pursuit of CytoDyn’s success through a renewed focus on the entrepreneurial spirit*. Leronlimab is a unique molecule with the potential to help many individuals, particularly with unmet medical needs. We will focus on enhancing shareholder value through* focused execution and refining of the path forward for leronlimab*.”*

Our Teams and Individuals, will become united in the Remodeling of CytoDyn by focusing on the execution of the entrepreneurial spirit, and the refining of the forward path of Strategic Partnership. This thinking forms the basis of our unification, now under developmental construction and it is ensuring that CytoDyn be established strong and solid enough to deal with the consequences of rapid expansion and growth. The developmental changes shall assuredly emerge, and these ensuing changes will ensure that CytoDyn maintains the same power it holds today, with which, in order to maintain grasp and developmental control over LRM's expansion, even when the violent winds start swirling with the coming approval of LRM.

CytoDyn shareholders are assured that Gilead will not be pleased in any way, shape or form, with any approval that LRM will receive. The first of which will be on the indication of HIV. Gilead will vehemently resist this, but they will need to come to terms with its reality, that LRM shall become an approved treatment for HIV in the coming months. Gilead will utterly lose it with an approval for LRM for mTNBC, especially if CytoDyn combines its strengths with a suiting Partner sporting a PD-1 checkpoint inhibitor which together, effectively & definitively treats both the tumor and the metastasis.

On the NASH front, Madrigal Pharmaceuticals, owner of Resmetirom, would become rather distraught with CytoDyn in its formation of an Alliance in the pursuit of NASH and NAFLD. For that matter, so would Pfizer. Madrigal Pharmaceuticals would be wise to combine and partner up with CytoDyn on a combination product sporting both Resmetirom as well as Leronlimab in combination to address both the steatosis as well as the fibrosis in NAFLD, NASH and possibly even cirrhosis.

CytoDyn and Partners in NDA discussions, lead at the head of the line in developments across the United States and in many parts of the globe, in research at universities, cancer centers and for the NIH, on these as well as many other unmet medical needs and indications which really, nobody has an effective solution for. CytoDyn does though.

In last conference call, Scott Kelly said: "On Partnerships, we will continue to pursue partnerships both internationally and domestically for Pharma companies, Academic Institutions, and government funding. We are doing this across multiple indication and we will announce any progress to investors when appropriate. Regarding presentations and publications, this has been exciting for scientific credibility, We did have poster presentation at San Antonio breast conference in December 2021. We had poster presentation America Association of Cancer Research 4/11/2022 by Dan Adams of Creative Microtech, We had a poster presentation at EASL Liver Congress in London, 6/25/22 for which I was present. We had a walking poster tour with the chairman and we are submitting more data to other conferences. We also had online abstract at ASCO regarding LRM by Dan Adams of cReative microtech.Regarding publications, we published an HIV monotherapy paper which is entitled Suppression of Human and Simian, Immunodeficiency Virus Replication with the CCR5 specific antibody LRM in 2 different species. We also submitted a paper on HIV and DR regarding CVO2 trial and we are awaiting response. We did a Covid 19 LH paper which is published in Clinical Infectious Disease."

Personally, I feel the reason CytoDyn is so shorted and so hated currently, is because, the majority of Big Pharma, does not want CytoDyn to Remodel, nor to Partner. Big Pharma does not want any Alliance at all to form between CytoDyn and anyone else for that matter, nor do they wish CytoDyn to improve and develop on their own. Regardless of the cutting edge technology of CCR5 inhibition and blockade, and the power it wields in saving lives, these entities prefer, that CytoDyn's human, monoclonal antibody, Leronlimab, just goes away along with the company that is developing it. These entities prove daily, that they are fighting tooth and nail to keep LRM from materializing into an FDA approved treatment.

The $5 million NIH grant, issued to OSHU and Dr. Jonas Sacha to research AAV adeno-associated virus vector technology to cure HIV, if successful would be an incredibly immense blow to Gilead and an equally immense support for CytoDyn as well as for patients with HIV. With such a reality, where HIV is cured, all the benefits of CCR5 blockade would permanently result. Therefore, in addition to being cured of HIV, patients would also realize tremendous permanent improvements/resolutions in their other ailments which they had prior to obtaining the treatment. That would lead to the broad, "off label" use of this AAV technology for other indications that some rich patients would pay out right for, because, it would not be covered by insurance being "off Label", but some patients will pay what ever it takes to permanently get rid of some ailments. Of course, it would have to be approved for HIV first.The expansion in the use of LRM via AAV delivery, has the potential to deliver a massive Earth shattering blow into the means by which Big Pharma operates. The industry would have a very hard time dealing with a cure to not just HIV, but what about a cure to numerous cancers? What about a cure to leukemia or of lymphoma? Or a cure to Long Haulers, or a cure to Graft vs. Host disease? How would they stomach that? Yes, these are only the tip of the iceberg. But, these are the implications...

With the guidance of Cyrus, CytoDyn is now in the process of Remodeling itself into becoming the kind of company capable of eventually delivering such cures that have the capacity to revolutionize the world. Dramatic and immense changes are on the way. CytoDyn now Remodels to transform so it becomes capable of dealing with the world it effected and the ramifications of such changes. Cyrus guides CytoDyn in understanding on how it must change, so it can develop LRM forward. He brings CytoDyn into Strategic Alliances, discusses management of such problems. CytoDyn's suiting partners need to be capable of facing any counter, made by Big Pharma, Big Media or Big Money, which will undoubtedly occur following the forging of these Alliances. Negotiations will need to be made with Big Pharma. CytoDyn is preparing to become a force to be reckoned with, and now is the time for discussing the pacts of concessions and compromise. How is it that normalcy will be maintained once LRM is approved? That should be one topic of discussion, because, that will become a necessary need to be filled, once LRM is approved. No one likes mayhem, but that will result if a pact is not made. LRM and suiting combination shall quickly move to the front of the line while the rest of Big Pharma will have to deal with its rise. Which Big Pharma will have the hardest time with a LRM/combo approval? Gilead.

Why don't we see Gilead or really any Big Pharma directly confront CytoDyn? Because they have their proxies do it for them in their stead. Gilead will not directly confront CytoDyn, but rather, they put their proxies up to the task on their behalf. Think about it. Do you think Amarex sabotaged CytoDyn's HIV BLA on their own initiative or were they put up to it?

Yet, because of the Strategic Partnerships being forged and aligned today, CytoDyn shall have the fortitude with which to stand against Gilead's proxies, in order to counter, to present its position in such a way, in order to develop Leronlimab against multiple indications, unabated for the period of the alliances, usually, for a minimum of 8-12 years, which is the typical duration of an FDA approved drug before it goes generic.

Look, isn't it crystal clear? How hard are we being fought against by Big Pharma? by Big Money? by Big Media? by the FDA? It is all around the stock, plain as day, even to the unobservant or the nonchalant. The absolute adamancy, the sheer will power, the determination, the motivation of the shorts to keep us smothered, choking us and holding us under water regardless of what they doll out monthly in interest charges to do it. Regardless of how many millions of shares they're forced to borrow and dump daily, (short), to maintain the low share price, just to maintain the onslaught, to prevent the long share holders from breathing, from taking a breath. Why? (I say the following sarcastically), so that CytoDyn can partner up?, and develop an alliance?, and get LRM approved and dominate multiple multibillion dollar indications? (Of course not.) Then Why? So that, Dr. Cyrus Arman, who is educated in the art of Strategy, can organize, Remodel and mold CytoDyn from inside/out, and develop into a multi-partnership conglomerate consisting of multiple Alliances which shall utterly transform Big Pharma into a tolerant zombie, industry wide, 180 degree and diametrically opposed to the changing effects which Leronlimab will effect by its CCR5 blockade monoclonal antibody treatment? Hell no! Some of Big Pharma shall flat out refuse to accept what shall happen, let alone tolerate any of these changes, however, Dr. Cyrus, will help pave the way to garner the support of our suiting partners to stand strong in the face of these assuredly coming challenges. Now, you all should know why CytoDyn is so vehemently hated and shorted.

I feel that the beginning of all this, is the fact that Dr. Cyrus Arman, with the kind of strategizing experience he has referenced in the PR, has come on board to exercise Strategic Partnerships and that a lot of this will take place before he is inaugurated as CEO, which is within 6 months. I believe he may effect more than one Alliance before the time he is inaugurated. What was written in the Press Release paints the Big Picture until he is inaugurated. CytoDyn's future stems on a Remodeling of CytoDyn and its shareholders into a conglomerate of multiple Strategic Partnerships. Cyrus Arman gets it done and gets us there. That's the picture I see painted. This is the reason for his presidency leading to CEO. At the same time, he gets paid well to execute on his plan.

​

//

Now, on the issue of Patents:

People, you need to understand, the Patent is not going to run out in February. The Patent that runs out in February is not the Patent CytoDyn has been using in the trials. The Patent that CytoDyn has been using in their trials which is called, "Concentrated Protein Formulation", runs out in 2031. Bashers want to push that it will run out in February, but that is just typical of what they do. They lie. The truth is, that there is nothing to fear with the Patent expiring in February. These are simply things that the shorts, who are running scared spread and distribute. Shorts are panicking and don't know what else to lie about, so they erringly say the Patent expires in February. But they refer to the Patent on the "Composition of Matter" which expires in February, which is not the Patent of importance, which is the "Concentrated Protein Formulation Patent", which will expire in 2031.

Here is Scott Kelly in last conference call:

"We want to address questions on Patents. I want people to understand that we have a highly qualified boutique firm that has handled our IP portfolio for many years. Since LRM is a biologic, it will receive 12 years of exclusivity if approved. The original patent composition of matter does expire in 2023, but the Concentrated Protein Formulation does not expire until 2031, and this is what has been used in all our clinical studies. We will also pursue methods that use patents LRM in a novel way across many indications."

and also here:

"43:56 Christine: So do we have a filed patent for each indication we use LRM on or is 1 patent overreaching?

Scott Kelly: So again to emphasize, our protein concentration formula that has been used in all our clinical trials, lasts until 2031. Now upon approval, biologics get 12 years of exclusivity, so we will continue to pursue methods of these patents which is essentially patents for LRM in various indications based on MOA."